Prof Pierre Conte speaks to ecancer at the BGICC 2020 conference in Cairo, Egypt about the management of patients with triple-positive breast cancer.
He explains that the prognosis of HR-positive patients is slightly better, compared to patients with HER-2 positive, HR-negative disease.
Prof Conte also the types of therapy available and the recent data from the APHINITY and ExteNET trials.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
